

# Irina Alecu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6061233/publications.pdf>

Version: 2024-02-01

14  
papers

636  
citations

840776

11  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

945  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulated Lipid Metabolism and Its Role in $\alpha$ -Synucleinopathy in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 328.	2.8	169
2	Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats. <i>Diabetes</i> , 2015, 64, 1035-1045.	0.6	69
3	HSAN1 mutations in serine palmitoyltransferase reveal a close structure-function-phenotype relationship. <i>Human Molecular Genetics</i> , 2016, 25, 853-865.	2.9	69
4	Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction. <i>Journal of Lipid Research</i> , 2017, 58, 42-59.	4.2	67
5	Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. <i>FASEB Journal</i> , 2015, 29, 4461-4472.	0.5	65
6	Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway. <i>Journal of Lipid Research</i> , 2017, 58, 60-71.	4.2	45
7	Altered sphingoid base profiles in type 1 compared to type 2 diabetes. <i>Lipids in Health and Disease</i> , 2014, 13, 161.	3.0	37
8	Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 568-575.	1.5	31
9	ORMDL3 expression levels have no influence on the activity of serine palmitoyltransferase. <i>FASEB Journal</i> , 2016, 30, 4289-4300.	0.5	27
10	Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 844-859.	3.9	18
11	Serine palmitoyltransferase assembles at ER-mitochondria contact sites. <i>Life Science Alliance</i> , 2022, 5, e202101278.	2.8	17
12	Oxidative stress increases 1-deoxysphingolipid levels in chronic kidney disease. <i>Free Radical Biology and Medicine</i> , 2021, 164, 139-148.	2.9	9
13	Disturbed sphingolipid metabolism with elevated 1-deoxysphingolipids in glycogen storage disease type I - A link to metabolic control. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 73-78.	1.1	7
14	1-deoxysphingolipids bind to COUP-TF to modulate lymphatic and cardiac cell development. <i>Developmental Cell</i> , 2021, 56, 3128-3145.e15.	7.0	6